Clinical TrialMay 12, 2026, 09:33 AM
Disc Medicine DISC-0974 Phase 2 RALLY-MF trial shows 70% overall response
AI Summary
Disc Medicine announced it will present data from multiple hematology programs at the European Hematology Association (EHA) 2026 Congress. The highlight is an oral presentation of Phase 2 RALLY-MF trial data for DISC-0974 in anemia of myelofibrosis, showing a 70% overall response rate among evaluable patients. The company will also provide updates on its bitopertin program for EPP and the DISC-3405 trial for polycythemia vera. Management will host a conference call on June 15 to discuss the presented data.
Key Highlights
- Disc Medicine to present data from multiple hematology programs at EHA 2026 Congress.
- Oral presentation of Phase 2 RALLY-MF trial data for DISC-0974 in anemia of myelofibrosis.
- DISC-0974 showed a 70% overall response rate among 43 evaluable patients.
- Major response rates were 54% (15/28) for non-transfusion dependent patients.
- Major response rates were 67% (6/9) for lightly transfused patients.
- Major response rates were 50% (3/6) for heavily transfused patients.
- Additional updates on bitopertin HELIOS study in EPP and DISC-3405 trial in polycythemia vera.
- Management will host a corporate update conference call on June 15 at 8:00 am ET.
Price Impact
More from IRON